Stocks

P&G Health India Sees Sales Growth and PAT Surge in Q1 FY27

Guavy AI Editorial Team Published August 6, 2026

Instruments

Procter & Gamble Health Ltd., the maker of vitamins, minerals, and supplement brands such as Neurobion, Livogen, and SevenSeas, reported a 7% year-on-year increase in sales to ₹356 crore for the quarter ended June 30, 2026. The company's profit after tax (PAT) surged 45% to ₹96 crore during the same period.

The revenue growth was attributed to strong brand fundamentals, improved retail execution, and positive consumer response to new product innovations. Excluding one-time proceeds from the sale of an immovable asset, operational PAT stood at ₹72 crore, up 9% from the year-ago period.

Milind Thatte, Managing Director of P&G Health India, stated that the company had begun FY27 on a strong footing, building on the momentum of the previous financial year. He added that performance was supported by consumer response to science-backed innovations and new communication initiatives.

P&G Health India Sees Sales Growth and PAT Surge in Q1 FY27

Merck's Oral Cholesterol-Lowering Peptide Gets FDA Approval

Merck Stock Holds Firm Above Key Levels After FDA Accepts RSV Filing

Merck Boosts Profit Guidance Amid Strong Demand for AI-Driven Materials